Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced the approval of inducement awards for eight new employees. The Compensation Committee of Avadel's Board of Directors granted non-statutory options to purchase 60,400 ordinary shares under the company's 2021 Inducement Plan.
The options come with a ten-year term and feature a four-year vesting schedule, with 25% vesting annually starting from each employee's first anniversary. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment acceptance.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato l'approvazione di premi di incentivo per otto nuovi dipendenti. Il Comitato per la Remunerazione del Consiglio di Amministrazione di Avadel ha concesso opzioni non statutarie per l'acquisto di 60.400 azioni ordinarie nell'ambito del Piano di Incentivazione 2021 dell'azienda.
Le opzioni hanno una durata di dieci anni e prevedono un piano di maturazione quadriennale, con il 25% che matura ogni anno a partire dal primo anniversario di ciascun dipendente. Questi premi sono stati concessi in conformità alla Regola 5635(c)(4) del Nasdaq come incentivo per l'accettazione dell'impiego.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha anunciado la aprobación de premios de inducción para ocho nuevos empleados. El Comité de Compensación del Consejo de Administración de Avadel otorgó opciones no estatutarias para comprar 60.400 acciones ordinarias bajo el Plan de Inducción 2021 de la empresa.
Las opciones tienen un plazo de diez años y cuentan con un calendario de adquisición de derechos de cuatro años, con el 25% adquiriéndose anualmente a partir del primer aniversario de cada empleado. Estos premios se otorgaron de acuerdo con la Regla 5635(c)(4) del Nasdaq como un incentivo para la aceptación del empleo.
Avadel Pharmaceuticals (나스닥: AVDL)는 8명의 신입 사원을 위한 유인 보상 승인 소식을 발표했습니다. Avadel 이사회 보상위원회는 회사의 2021년 유인 계획에 따라 60,400주 보통주를 매수할 수 있는 비법정 옵션을 부여했습니다.
옵션은 10년 만기이며, 4년간 매년 25%씩 권리 취득하는 스케줄이 적용되어 각 직원의 첫 번째 기념일부터 시작됩니다. 이 보상은 고용 수락 유인을 위한 나스닥 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Avadel Pharmaceuticals (Nasdaq : AVDL) a annoncé l'approbation de primes d'incitation pour huit nouveaux employés. Le comité de rémunération du conseil d'administration d'Avadel a accordé des options non statutaires pour l'achat de 60 400 actions ordinaires dans le cadre du Plan d'Incitation 2021 de la société.
Les options ont une durée de dix ans et suivent un calendrier d'acquisition étalé sur quatre ans, avec 25 % qui acquièrent chaque année à partir du premier anniversaire de chaque employé. Ces primes ont été accordées conformément à la règle 5635(c)(4) du Nasdaq en tant qu'incitation à l'acceptation de l'emploi.
Avadel Pharmaceuticals (Nasdaq: AVDL) hat die Genehmigung von Anreizprämien für acht neue Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Vorstands von Avadel hat nichtstatutarische Optionen zum Kauf von 60.400 Stammaktien im Rahmen des Inducement-Plans 2021 des Unternehmens gewährt.
Die Optionen haben eine Laufzeit von zehn Jahren und beinhalten einen vierjährigen Vesting-Zeitraum, wobei 25 % jährlich ab dem ersten Jahrestag jedes Mitarbeiters vesten. Diese Prämien wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die Annahme der Beschäftigung gewährt.
- None.
- None.
DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Alyssa Ramirez
Real Chemistry
aramirez@realchemistry.com
FAQ
What type of stock options did Avadel Pharmaceuticals (AVDL) grant to new employees?
What is the vesting schedule for Avadel's (AVDL) new employee stock options?
How long is the term of the stock options granted by Avadel (AVDL)?
Under which rule were Avadel's (AVDL) inducement awards granted?
